Medication info
Dapagliflozin Metformin Extended-Release Tablet 10/1000 mg

Dapagliflozin Metformin Extended-Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Vivozon Pharmaceutical Co., Ltd.
Appearance
Yellow, oval-shaped, double-convex extended-release film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202300354 · Approved 2023.01.27 · Insurance code 658204720

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient’s current dose of metformin or the nearest appropriate therapeutically equivalent dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue, such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Ingredients

Manufacturer
Vivozon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to assist in the control of blood sugar in adult patients with type 2 diabetes who require a combination of dapagliflozin and metformin. It is especially effective in managing blood sugar when used in conjunction with dietary control and exercise. It may also be used in type 2 diabetes patients who have cardiovascular disease or risk factors associated with cardiovascular disease when blood sugar control is challenging. Detailed information regarding the occurrence of cardiovascular events can be referenced in professional materials. This medication is intended to help improve blood sugar regulation.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient’s current dose of metformin or the nearest appropriate therapeutically equivalent dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue, such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Precautions

This medication helps in the management of blood sugar levels. Caution is required as there is a rare possibility of severe lactic acidosis being a side effect when taking this medication. If taken with other diabetes medications, there may be a risk of hypoglycemia. This medication should not be used in specific patients. For instance, patients with severely impaired kidney function, those with dehydration or severe infections, type 1 diabetes patients, heart failure patients, women who are pregnant or nursing, and those with lactose intolerance should not take this medication. Additionally, caution is required for patients with mildly reduced kidney function or low fluid volume. Elderly patients or those on diuretics also need to be cautious. Symptoms of hypotension or changes in kidney function should be closely monitored during treatment with this medication. Genital infections or urinary tract infections may occur frequently while taking this medication. If symptoms of infection appear in the genitals or urinary tract, immediate treatment is necessary. Additionally, hypoglycemic symptoms may occur, thus maintaining proper blood sugar management is important. This medication can lead to dehydration or hypotension due to reduced fluid volume, so fluid status should be well managed, and in necessary cases, discontinuation of the medication may be required. Rarely, serious metabolic disturbances such as diabetic ketoacidosis may occur, so if symptoms like abdominal pain, vomiting, or breathing difficulties occur, consult a healthcare professional immediately. This medication may lower vitamin B12 levels, so it is advisable to check for vitamin B12 deficiency if used for a long period. Alcohol consumption may increase the risk of side effects associated with this medication and should be avoided. Pregnant or nursing women should not use this medication, and use should be discontinued upon confirmation of pregnancy. Elderly patients should be aware that declining kidney function is common; therefore, renal function should be regularly monitored before and after use, and dosage adjustments may be necessary. In case of overdose, appropriate treatment should be administered, particularly since the metformin component can be removed through dialysis. This medication does not significantly affect driving or machinery operation, but caution is advised due to the possibility of dizziness. Finally, this medication should be kept out of the reach of children and maintained in its original container to preserve quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 87 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • gastrointestinal stromal tumors
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasions
  • benign prostatic hyperplasia
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensory hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to avoid contact with air or moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Yellow, oval-shaped, double-convex extended-release film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.